Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review

Despite being routinely prescribed worldwide for several years, data regarding the safety, efficacy, and survival benefit of eribulin in clinical settings for the treatment of metastatic breast cancer (MBC) are limited. This retrospective observational study investigated the survival benefit of erib...

Descripción completa

Detalles Bibliográficos
Autor principal: Watanabe, Junichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627999/
https://www.ncbi.nlm.nih.gov/pubmed/26543760
http://dx.doi.org/10.1186/s40064-015-1422-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627999/
https://www.ncbi.nlm.nih.gov/pubmed/26543760
http://dx.doi.org/10.1186/s40064-015-1422-8

Ejemplares similares